Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CCA, ERP, FVT

Imageware Provides Corporate Update and Plans for Conference Call


SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- Imageware® (OTCQB: IWSY) ("Imageware" or "the Company"), a leader in biometric identification and authentication solutions, today provided a corporate update.

Recent Highlights

Management Commentary

"We continue to work with Imperial Capital as they review strategic alternatives for the company. In our review process, all options remain on the table including the sale of certain assets, strategic partnerships, and sale of Imageware," said Company Chair, President, and CEO Kristin Taylor. "We believe our sales and marketing efforts should begin translating into new sales later this year. We also recorded the first official sale for our Law Enforcement 2.0 SaaS platform, and we anticipate going live with this new product in the coming months. With an improved senior leadership team, revamped go-to-market strategies, and new product launches on the horizon, Imageware is well-positioned for the coming quarters, which should translate to incrementally improved operating results going forward."

At quarter-end, the Company had $1.7 million in cash and cash equivalents, compared to $8.3 million on December 31, 2020.

Conference Call

Imageware management will hold a conference call during the week of December 6, 2021 to provide a corporate update. Details for the event will be provided at a later date.

About Imageware®

Imageware identifies, verifies, and authenticates who people are, not just what keys and codes they have. Our Cloud-based, multimodal biometric solutions provide faster, accurate identification to better secure communities, data, and assets. Imageware solutions are trusted globally by government agencies, law enforcement, and private enterprises. Imageware: Identity with Biometric Certainty. For more information, please visit www.imageware.io.

Forward-Looking Statements

Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "if," "should" and "will" and similar expressions as they relate to Imageware are intended to identify such forward-looking statements. Imageware may from time to time update publicly announced projections, but it is not obligated to do so. Any projections of future results of operations should not be construed in any manner as a guarantee that such results will in fact occur. These projections are subject to change and could differ materially from final reported results. Factors that may cause the projections to change or differ may include, but are not limited to, the ability to of the Company to continue to grow revenue, the ability to decrease operating expenses and continue to grow profit margins, and the Company's ability to continue to achieve positive cash flow given the Company's existing and anticipated operating and other costs. For a discussion of additional risks and uncertainties, see "Risk Factors" in Imageware's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and its other reports filed with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made.

Media Contact: 

Theresa Hernandez
Imageware
[email protected]

Investor Relations:

Brian M. Prenoveau, CFA
MZ North America
+1-561-489-5315
[email protected]

SOURCE ImageWare Systems, Inc.


These press releases may also interest you

at 06:15
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Exciting technical...

at 06:10
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The 2-year grant...

at 06:08
Aesthetic Management Partners LLC, a manufacturer of skin-based solutions and a provider of energy-based devices announces its collaboration with Croma (Croma-Pharma® GmbH), a global player in the minimally invasive aesthetics market and a leading...

at 06:05
The 2023 U.S. soybean field trials conducted by Texas Crop Science (TCS) demonstrated an average yield increase of 21% in soybean lines incorporating the TCS yield trait. This breakthrough in performance would generate approximately $121 per acre in...

at 06:05
3EO Health, a "Point of Life" diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable. Today, the company has published...

at 06:05
Zura Bio Limited ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights. The Company has also...



News published on and distributed by: